PGRMC1 and PAQR4 are promising molecular targets for a rare subtype of ovarian cancerKamila Kozłowska-Tomczyk, Anna Ptak|Open Life Sciences|2024Cited by 3
Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Aneta Bobowska et al.|Cancer Research|2025Cited by 1